Suchergebnisse - "Gao, George Fu"

PubPharm (16)

1

Broad-spectrum Delta-BA.2 tandem-fused heterodimer mRNA vaccine delivered by lipopolyplex

enthalten in: PLoS pathogens | 2024

von Du, P. | Huang, L. | Fang, Y. | +9

2

Long-term effects of Omicron BA.2 breakthrough infection on immunity-metabolism balance : a 6-month prospective study

enthalten in: Nature communications | 2024

von Li, Y. | Qin, S. | Dong, L. | +11

3

Defining a de novo non-RBM antibody as RBD-8 and its synergistic rescue of immune-evaded antibodies to neutralize Omicron SARS-CoV-2

enthalten in: Proceedings of the National Academy of Sciences of the United States of America | 2023

von Rao, X. | Zhao, R. | Tong, Z. | +22

4

Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3-17 years in China : a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial

enthalten in: The Lancet. Child & adolescent health | 2023

von Gao, L. | Li, Y. | He, P. | +19

5

A broadly neutralizing nanobody targeting the highly conserved S2 subunit of sarbecoviruses

enthalten in: Science bulletin | 2023

von Wang, X. | Xie, Y. | Liu, H. | +7

6

Cross-reaction of current available SARS-CoV-2 MAbs against the pangolin-origin coronavirus GX/P2V/2017

enthalten in: Cell reports | 2022

von Jia, Y. | Niu, S. | Hu, Y. | +15

7

Atlas of currently available human neutralizing antibodies against SARS-CoV-2 and escape by Omicron sub-variants BA.1/BA.1.1/BA.2/BA.3

enthalten in: Immunity | 2022

von Huang, M. | Wu, L. | Zheng, A. | +24

8

An engineered bispecific human monoclonal antibody against SARS-CoV-2

enthalten in: Nature immunology | 2022

von Li, Z. | Li, S. | Zhang, G. | +22

CommentIn: Nat Immunol. 2022 Mar;23(3):346-347. - PMID 35228693

9

Recombinant SARS-CoV-2 RBD with a built in T helper epitope induces strong neutralization antibody response

enthalten in: Vaccine | 2021

von Su, Q. | Zou, Y. | Yi, Y. | +18

10

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV : a randomised, double-blind, placebo-controlled, phase 1/2 trial

enthalten in: The Lancet. Infectious diseases | 2021

von Xia, S. | Zhang, Y. | Wang, Y. | +29